MANDALUYONG, Philippines and LAUSANNE, Switzerland, December 7, 2015 /PRNewswire/ --
Pamorelin® one-, three- and six-month dosing option now available to patients in the Philippines
United Laboratories Inc. (Unilab) and Debiopharm International SA (Debiopharm) announce the signature of an exclusive agreement for the distribution and commercialization of Pamorelin® 1, 3, and 6-month formulations in the Philippines, for the treatment of locally advanced and metastatic hormone-dependent prostate cancer and as adjuvant to radiotherapy in high-risk localized and locally advanced prostate cancer, and for the treatment of endometriosis (1- and 3-month formulations only).
Developed by Debiopharm, the product is manufactured in Switzerland by Debiopharm Research & Manufacturing SA and imported in the Philippines by Unilab. Pamorelin® LA will be made available primarily to urologists, oncologists and gynecologists across the Philippines.
"Our partnership with Debiopharm International SA adds more value to our mission as a pharmaceutical company that provides access to quality and affordable healthcare products and services," says Jose Maria A. Ochave, Senior Vice President for Business Development Group of Unilab. "Our collaboration marks a significant step toward achieving a shared goal of providing options for better quality of life to more patients."
"We are very happy to broaden the availability of our therapy for locally advanced and metastatic prostate cancer in Asia," said Thierry Mauvernay, Co-President, Delegate of the Board of Debiopharm Group. "Prostate cancer is one of the most common cancers in men and we are keen on improving the quality of life of these patients. We are also pleased to offer a treatment option to women suffering from endometriosis."
About Pamorelin® LA (active ingredient: triptorelin)
Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). Debiopharm has developed three sustained-release formulations (1, 3 and 6 months) of triptorelin pamoate. The 1- and 3-month formulations have already been registered in numerous countries and are available under different brand names: Trelstar®, Decapeptyl® and Pamorelin®. The 6-month formulation has been registered and is available in Singapore, Europe, the US and Latin America.
About United Laboratories, Inc.
Unilab is the biggest pharmaceutical company in the Philippines, with a market share of more than 20 percent which it has consistently maintained for more than three decades. Its portfolio includes some of the biggest prescription, consumer healthcare and personal care brands in the country.
For more information, please visit http://www.unilab.com.ph/
About Debiopharm International SA
Debiopharm Group™ is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investment management. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.
For more information, please visit http://www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
Debiopharm International SA Contact
Additional Media Contacts
In New York
Russo Partners, LLC
United Laboratories Inc. Contact
Claire D. Papa
External Affairs Director
SOURCE Debiopharm Group